CD274 and gastric cancer: In the RATIONALE-305 trial, tislelizumab plus chemotherapy demonstrated statistically significant improvement in OS, PFS, and ORR compared to placebo plus chemotherapy in patients with PD-L1-positive gastric cancer (GC)/gastroesophageal junction cancer (GEJC) [6].